CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 23 enrolled
Drug / intervention
Raltegravirdrug
Likely dose
Raltegravir 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01767701
NCT01767701Phase 2Completed
CompareCT.gov

A Phase II Baseline Versus Treatment Study to Determine the Efficacy of Raltegravir (Isentress) in Preventing Progression of Relapsing Remitting Multiple Sclerosis as Determined by Gadolinium-enhanced MRI

Queen Mary University of London·interventional·Posted Jan 14, 2013·Updated May 30, 2017

In Brief

A Phase 2 clinical trial evaluating Raltegravir for Relapsing Remitting Multiple Sclerosis. Completed, enrolled 23 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether raltegravir is effective in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium- enhanced MRI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Remitting Multiple Sclerosis
CountriesUnited Kingdom
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 14, 2013
Enrollment StartApr 1, 2013
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.5 years ago

Interventions

Raltegravirdrug

400mg twice daily for 3 months